skip to main content

brainstorm askiatroX medicines

simulations beta

loading page…

learn & practise

exams international doctors free questions Socratic Tutor rounds stat clinical connections academy journal tool guides

clinical reference

askiatroX knowledge centre medicines UK / NICE guidance international guidance calculators q&a library

trust & support

how it works methodology account & support frequently asked questions about us clinical safety consultancy

legal

mobile app · scan to download

Medicines regorafenibQuestion & answer

regorafenib · Medicine question

Must breastfeeding be discontinued during treatment with regorafenib?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Yes, breastfeeding must be discontinued during treatment with Stivarga (regorafenib).

Sources for this answer

Stivarga 40 mg film coated tabletsBayer plc · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 7Document updated 2 June 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

The full medicine guide

regorafenib

More questions about regorafenib

Under what circumstances may regorafenib be used during pregnancy?What is known about the effects of regorafenib on male and female fertility?What hypersensitivity contraindicates treatment with Stivarga (regorafenib)?What prior treatment is required for adults receiving regorafenib (Stivarga) for hepatocellular carcinoma?Which adults with gastrointestinal stromal tumours are eligible for regorafenib (Stivarga) treatment?Which adults with metastatic colorectal cancer are eligible for regorafenib (Stivarga) treatment?

Read the wider context, including uses, precautions and the sources behind this medicine guide.

Read the regorafenib guide

More clinical questions?

Explore the tools and reference material available on iatroX.

Explore askiatroX